Your browser is no longer supported. Please, upgrade your browser.
Autolus Therapeutics plc
Index- P/E- EPS (ttm)-2.69 Insider Own25.58% Shs Outstand62.45M Perf Week6.74%
Market Cap413.95M Forward P/E- EPS next Y-1.92 Insider Trans0.00% Shs Float33.90M Perf Month-15.68%
Income-145.50M PEG- EPS next Q-0.50 Inst Own36.70% Short Float5.79% Perf Quarter2.99%
Sales1.60M P/S258.72 EPS this Y4.20% Inst Trans15.36% Short Ratio0.95 Perf Half Y-20.92%
Book/sh4.80 P/B1.22 EPS next Y3.50% ROA-45.80% Target Price- Perf Year-55.61%
Cash/sh3.38 P/C1.73 EPS next 5Y- ROE-57.90% 52W Range4.60 - 16.78 Perf YTD-34.45%
Dividend- P/FCF- EPS past 5Y-53.50% ROI-68.60% 52W High-66.60% Beta-
Dividend %- Quick Ratio9.40 Sales past 5Y7.20% Gross Margin- 52W Low21.85% ATR0.45
Employees376 Current Ratio9.40 Sales Q/Q0.00% Oper. Margin- RSI (14)42.05 Volatility7.78% 7.19%
OptionableYes Debt/Eq0.00 EPS Q/Q11.10% Profit Margin- Rel Volume1.79 Prev Close5.86
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume2.06M Price5.61
Recom2.00 SMA20-7.03% SMA50-14.11% SMA200-27.09% Volume1,809,957 Change-4.35%
Jun-14-21Upgrade Jefferies Hold → Buy $6 → $12
Jan-29-21Downgrade JP Morgan Overweight → Neutral $9
Dec-28-20Resumed H.C. Wainwright Buy $19
Jul-31-20Initiated JP Morgan Overweight
Jul-22-20Initiated SunTrust Buy $38
Apr-22-20Initiated Mizuho Buy $18
Sep-23-19Initiated Needham Buy $26
May-17-19Reiterated H.C. Wainwright Buy $45 → $41
Oct-24-18Initiated H.C. Wainwright Buy $45
Aug-02-21 12:33PM  
Jul-15-21 07:00AM  
Jul-08-21 07:00AM  
Jun-15-21 07:00AM  
Jun-11-21 09:43AM  
Jun-06-21 03:17AM  
May-25-21 07:00AM  
May-21-21 07:00AM  
May-13-21 08:32AM  
May-12-21 03:42PM  
May-06-21 07:00AM  
Apr-26-21 07:00AM  
Apr-20-21 07:00AM  
Apr-19-21 07:00AM  
Apr-07-21 01:51AM  
Apr-01-21 04:01PM  
Mar-29-21 08:00AM  
Mar-04-21 07:00AM  
Mar-03-21 10:43AM  
Mar-02-21 04:18AM  
Feb-24-21 07:00AM  
Feb-12-21 04:01PM  
Feb-10-21 06:59AM  
Feb-09-21 08:42PM  
Feb-08-21 04:19PM  
Feb-05-21 12:57AM  
Feb-04-21 07:00AM  
Jan-27-21 12:00PM  
Jan-06-21 04:07AM  
Jan-04-21 07:00AM  
Dec-07-20 12:01PM  
Dec-05-20 03:01PM  
Dec-04-20 10:14AM  
Dec-01-20 08:55AM  
Nov-30-20 07:00AM  
Nov-17-20 07:00AM  
Nov-07-20 07:47AM  
Nov-06-20 05:30AM  
Nov-05-20 07:00AM  
Oct-30-20 07:00AM  
Sep-18-20 03:05AM  
Sep-08-20 07:00AM  
Sep-01-20 07:48AM  
Aug-06-20 07:00AM  
Aug-05-20 10:05AM  
Aug-04-20 07:00AM  
Jul-30-20 07:00AM  
Jul-02-20 04:39PM  
Jun-24-20 09:32AM  
Jun-22-20 07:00AM  
Jun-19-20 11:30AM  
Jun-12-20 02:30AM  
Jun-08-20 05:00PM  
Jun-03-20 06:28AM  
Jun-02-20 08:07AM  
May-29-20 07:37AM  
May-26-20 07:00AM  
May-22-20 07:00AM  
May-15-20 11:20AM  
May-14-20 07:00AM  
May-13-20 09:27AM  
May-12-20 12:00PM  
May-10-20 08:26AM  
May-09-20 11:01PM  
May-07-20 08:06AM  
May-01-20 07:00AM  
Apr-16-20 07:00AM  
Mar-03-20 07:07AM  
Feb-25-20 07:00AM  
Feb-24-20 07:00AM  
Jan-30-20 07:00AM  
Jan-27-20 04:00PM  
Jan-22-20 09:41PM  
Jan-13-20 07:00AM  
Jan-08-20 11:48AM  
Dec-20-19 06:30AM  
Dec-18-19 07:59AM  
Dec-14-19 07:47PM  
Dec-08-19 09:15AM  
Dec-07-19 02:00PM  
Dec-05-19 04:30PM  
Nov-27-19 07:03AM  
Nov-18-19 04:52AM  
Nov-13-19 04:02PM  
Nov-09-19 07:00AM  
Nov-07-19 07:06AM  
Nov-06-19 09:24AM  
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.